Despite the unfavorable ruling in the IPR at the USPTO, AMGN/AGN still can—and probably will—launch its Humira FoB in the US market (pending FDA approval) and take its chances in court (#msg-118766059). Knocking out ABBV’s Humira patents via the IPR was Plan A… prevailing in a patent trial is Plan B. There’s also a possibility for a settlement.
Market Data 
Markets 
AI
